Warfarin pharmacogenetics in a black Zimbabwean cohort: an observational prospective study.

IF 1.9 4区医学 Q3 PHARMACOLOGY & PHARMACY

Pharmacogenomics Pub Date : 2023-07-01 Epub Date: 2023-07-12 DOI:10.2217/pgs-2023-0089

Marie Madeleine M Hidjo, Zedias Chikwambi, Gift Ngwende, Jonathan A Matenga, Collen Masimirembwa

{"title":"Warfarin pharmacogenetics in a black Zimbabwean cohort: an observational prospective study.","authors":"Marie Madeleine M Hidjo, Zedias Chikwambi, Gift Ngwende, Jonathan A Matenga, Collen Masimirembwa","doi":"10.2217/pgs-2023-0089","DOIUrl":null,"url":null,"abstract":"Aim: A prospective observational study was conducted to evaluate the feasibility of implementing clinical guidelines for warfarin dosing in black Zimbabwean patients. Methods: CYP2C9*5, CYP2C9*6, CYP2C9*8 and CYP2C9*11 and VKORC1 c. 1639 G>A variations were observed in 62 study patients. Results & Conclusion: Overall, 39/62 (62.90%) participants did not receive a warfarin starting dose as would have been recommended by Clinical Pharmacogenetics Implementation Consortium guidelines. US FDA and Dutch Pharmacogenetics Working Group guidelines are based on CYP2C9*2 and CYP2C9*3 only, hence, unlikely useful in this cohort, where such variants were not detected. Clinical Pharmacogenetics Implementation Consortium guidelines, on the other hand, have a specific recommendation on the African-specific variants CYP2C9*5, CYP2C9*6 and CYP2C9*11, and are hence suitable for implementation in Zimbabwe and would help optimize warfarin doses in patients in the study cohort.","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":"24 10","pages":"529-538"},"PeriodicalIF":1.9000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10621760/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacogenomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/pgs-2023-0089","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/7/12 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: A prospective observational study was conducted to evaluate the feasibility of implementing clinical guidelines for warfarin dosing in black Zimbabwean patients. Methods: CYP2C9*5, CYP2C9*6, CYP2C9*8 and CYP2C9*11 and VKORC1 c. 1639 G>A variations were observed in 62 study patients. Results & Conclusion: Overall, 39/62 (62.90%) participants did not receive a warfarin starting dose as would have been recommended by Clinical Pharmacogenetics Implementation Consortium guidelines. US FDA and Dutch Pharmacogenetics Working Group guidelines are based on CYP2C9*2 and CYP2C9*3 only, hence, unlikely useful in this cohort, where such variants were not detected. Clinical Pharmacogenetics Implementation Consortium guidelines, on the other hand, have a specific recommendation on the African-specific variants CYP2C9*5, CYP2C9*6 and CYP2C9*11, and are hence suitable for implementation in Zimbabwe and would help optimize warfarin doses in patients in the study cohort.

查看原文本刊更多论文

津巴布韦黑人队列中的华法林药物遗传学：一项观察性前瞻性研究。

目的：进行一项前瞻性观察性研究，以评估在津巴布韦黑人患者中实施华法林给药临床指南的可行性。方法：CYP2C9*5、CYP2C9*6、CYP2C9*8和CYP2C9*11和VKORC1c。在62名研究患者中观察到1639G>A变异。结果与结论：总体而言，39/62（62.90%）的参与者没有按照临床药物遗传学实施联盟指南的建议接受华法林起始剂量。美国食品药品监督管理局和荷兰药物遗传学工作组指南仅基于CYP2C9*2和CYP2C9*3，因此，在未检测到此类变异的队列中不太可能有用。另一方面，临床药物遗传学实施联盟指南对非洲特异性变体CYP2C9*5、CYP2C9*6和CYP2C9*11有具体建议，因此适合在津巴布韦实施，并有助于优化研究队列中患者的华法林剂量。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmacogenomics 医学-药学

CiteScore

3.40

自引率

9.50%

发文量

审稿时长

4-8 weeks

期刊介绍： Pharmacogenomics (ISSN 1462-2416) is a peer-reviewed journal presenting reviews and reports by the researchers and decision-makers closely involved in this rapidly developing area. Key objectives are to provide the community with an essential resource for keeping abreast of the latest developments in all areas of this exciting field. Pharmacogenomics is the leading source of commentary and analysis, bringing you the highest quality expert analyses from corporate and academic opinion leaders in the field.